Patient Access Solutions Market worth 1.74 Billion USD by 2022

 According to a new market research report "Patient Access Solutions Marketby Product & Service (Eligibility Verification, Medical Necessity, Prior-authorization, Denial Management), Delivery Mode (Web & Cloud, On-premise), End User (Providers, Outsourcing Companies) - Global Forecast to 2022", published by MarketsandMarkets™, the market is expected to reach USD 1.74 Billion by 2022 from an estimated USD 1.21 Billion in 2017, at a CAGR of 7.6%. Regulatory compliance encouraging the use of patient access solutions, increasing patient volume and the subsequent growth in the demand for health insurance, growing importance of denial management, declining reimbursement rates, and need to curtail escalating healthcare costs are the major factors driving the growth of the patient access solutions market.

Browse 62 market data Tables and 34 Figures spread through 145 Pages and in-depth TOC on "Patient Access Solutions Market"
https://www.marketsandmarkets.com/Market-Reports/patient-access-solution-market-280473.html
Early buyers will receive 10% customization on this report

"By product & service, the services segment accounted for the largest share of the patient access solutions market in 2016." 

On the basis of product & service, the services segment accounted for the largest share of the global patient access solutions market. The introduction of complex software and the need for system integration are expected to boost the services market in the near future.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=280473

"By delivery mode, the web & cloud-based solutions segment accounted for the largest share of the patient access solutions market in 2016." 

On the basis of delivery mode, the web & cloud-based solutions segment accounted for the largest share of the global patient access solutions market. This segment is also exected to grow at the highest CAGR during the forecast period. Factors such as flexibility of working from remote areas, rising affordability, and features such as auto-upgradation are attributing to the larger share and high growth of the web & cloud-based solutions segment.

"By end users, the healthcare providers segment held the largest market share of patient access solutions market in 2016." 

Based on end user, the healthcare providers segment accounted for the largest share of the patient access solutions market. Increasing healthcare IT adoption, increasing affordability in developing countries, and increasing volume of claims denials are the major factors supporting the adoption of patient access solutions in healthcare providers.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownload.asp?id=280473 

Bioinformatics Market | Size, Share, Trends, Growth and Forecast

According to research report the Bioinformatics Market is projected to reach USD 13.50 billion in 2023 from USD 7.73 billion in 2018, at CAGR of 14.5%

According to research report the Bioinformatics Market is projected to reach USD 13.50 billion in 2023 from USD 7.73 billion in 2018, at CAGR of 14.5%. Growing demand for nucleic acid and protein sequencing, initiatives from government and private organizations, growing applications of bioinformatics, and the increasing number of collaborations between companies and research institutes are the major factors driving the growth of the market.
Based on product and service, the bioinformatics platforms segment is projected to grow at the highest CAGR in the market during the forecast period

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=39 
Based on applications, the genomics segment is estimated to account for the largest share of the market in 2018

Based on sector, the medical biotechnology segment is estimated to account for the largest share of the market in 2018
On the basis of sector, the global bioinformatics market is divided into medical biotechnology, academics, animal biotechnology, agricultural biotechnology, environmental biotechnology, and forensic biotechnology. The medical biotechnology is again subdivided into drug discovery & development, clinical diagnostics & precision medicine, reproductive health. In 2018, the medical biotechnology segment is estimated to account for the largest share of the bioinformatics market. The rising adoption of bioinformatics tools in pharmaceutical and clinical applications is driving market growth.

Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=39
Market Players
The bioinformatics market is highly competitive due to the presence of a large number of players. Few of the major companies in bioinformatics market are Thermo Fisher Scientific (US), Illumina Inc (US), Agilent Technologies (US), QIAGEN (Netherlands), BGI (China), Wuxi NextCODE (China), Eurofins Scientific (Luxembourg), Waters Corporation (US), Sophia Genetics (Switzerland), Partek (US), and DNASTAR (US).

Visit : https://www.marketsandmarkets.com/Market-Reports/bioinformatics-39.html

Biologics Safety Testing Market - Trend, Scope, Size, Share, Analysis

The biologics safety testing market was valued at USD 2.75 Billion in 2017 and is expected to grow at a CAGR of 12.2% to reach USD 4.90 Billion in 2022.

Growth in pharmaceutical and biotechnology industry driven by government support in both industries, the positive trend of R&D investment in the life sciences industry and an increase in the number of new drug launches are the major factors driving the growth of this market.

 The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation—by product & service, test type, application, and region) through percentage splits from secondary and primary research.

Download PDF Brochure: https://t.ly/Bdq1L

Biologics Safety Testing Market segmentation

•             By Product & Service

•             By Test Type

•             By Application

•             By Region

The Major Players Operating in the Biologics Safety Testing Market

Key players operating in the biologics safety testing market include Lonza Group LTD. (Switzerland), Charles River Laboratories (U.S.), Merck KGaA (Germany), SGS SA (Switzerland), WuXi Apptec (China), Thermo Fisher Scientific Inc. (U.S.), Sartorius AG (Germany), Cytovance Biologics, Inc. (U.S.), Pace Analytical Services Inc. (U.S.), and Toxikon Corporation (U.S.).

Geographical Detailed Analysis for Biologics Safety Testing Market:

By region, the global biologics safety testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While North America holds the largest share of the market in 2016, Asia is expected to grow at the highest CAGR during the forecast period. The presence of emerging economies like China and India; large population; growth in pharmaceutical and biotechnology industry; and growth in the outsourcing industry in this region are key factors driving the high growth of this regional segment.

Read More in Detailed (Biologics Safety Testing Market):

https://www.marketsandmarkets.com/Market-Reports/biologics-safety-testing-market-34624144.html

Biologics Safety Testing Market - Trend, Scope, Size, Share, Analysis

The biologics safety testing market was valued at USD 2.75 Billion in 2017 and is expected to grow at a CAGR of 12.2% to reach USD 4.90 Billion in 2022.

Growth in pharmaceutical and biotechnology industry driven by government support in both industries, the positive trend of R&D investment in the life sciences industry and an increase in the number of new drug launches are the major factors driving the growth of this market.

The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentation—by product & service, test type, application, and region) through percentage splits from secondary and primary research.

Download PDF Brochure: https://t.ly/Bdq1L

Biologics Safety Testing Market segmentation

•             By Product & Service

•             By Test Type

•             By Application

•             By Region

The Major Players Operating in the Biologics Safety Testing Market

Key players operating in the biologics safety testing market include Lonza Group LTD. (Switzerland), Charles River Laboratories (U.S.), Merck KGaA (Germany), SGS SA (Switzerland), WuXi Apptec (China), Thermo Fisher Scientific Inc. (U.S.), Sartorius AG (Germany), Cytovance Biologics, Inc. (U.S.), Pace Analytical Services Inc. (U.S.), and Toxikon Corporation (U.S.).

Geographical Detailed Analysis for Biologics Safety Testing Market:

By region, the global biologics safety testing market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). While North America holds the largest share of the market in 2016, Asia is expected to grow at the highest CAGR during the forecast period. The presence of emerging economies like China and India; large population; growth in pharmaceutical and biotechnology industry; and growth in the outsourcing industry in this region are key factors driving the high growth of this regional segment.

Read More in Detailed (Biologics Safety Testing Market):

https://www.marketsandmarkets.com/Market-Reports/biologics-safety-testing-market-34624144.html

Walking Assist Devices Market - Global Growth, Trends, and Forecast | MarketsandMarkets™

According to the new market research report “Walking Assist Devices Market by Product Type (Gait Belts & Lift Vests, Canes, Crutches, Walker, Wheelchairs, Power Scooters), and Region (North America, Europe, Asia-Pacific and ROW) - Global Forecast to 2020

",published by MarketsandMarkets™. The global walking assist devices market is expected to reach USD 6.57 Billion by 2020, at a CAGR of 3.9% from 2015 to 2020.

Don’t miss out on business opportunities in Walking Assist Devices Market.

The global market is expected to witness growth in the coming years, owing to factors such as the increase in the number of initiatives undertaken by governments of various countries to ensure availability of walking assist devices to a huge consumer base, rise in aging population, and increasing incidences of Debilitating Neurological Diseases & Injuries. Moreover, the trends in patient community and growing technological advancements & product leasing are also expected to drive the growth of the market. However, cost of purchase of walking assist devices is high.

Browse and in-depth TOC on "Walking Assist Devices Market"

108  - Tables

112  - Figures

Get Free 10% customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=24035174

Market Segmentation, by Product:

o   Gaits Belts & Lift Vests,

o   Canes

o   Crutches

o   Walkers

o   Wheelchairs

o   Power scooters

Customization Options

Along with market data, customize the MNM assessments to meet your company’s specific needs. Customize to get a comprehensive summary of the industry standards and a detailed analysis of the following parameters:

1.      Product Analysis

o   Usage pattern (in-depth trend analysis) of products (segment-wise)

o   Product matrix, which gives a detailed comparison of product portfolio of each company, mapped at country and subsegment level

o   End user adoption rate analysis of the products (segment-wise and country-wise)

o   Comprehensive coverage of product approvals, volume data, pipeline products, and product recalls

2.      Brand/Product Perception Matrix

o   Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking virality and tonality of blogs

o   Analysis of overall brand usage and familiarity, and brand advocacy distribution (detractor/neutral/familiar)

3.      1.1.3 PO RT E R ’S FI V E FO RC E S Analysis

o   Detailed account of the nature of bargaining power of the suppliers and the buyers

o   Degree and intensity of rivalry of the peer players and threat from the new entrants

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Vaccine Adjuvants Market | Growth, Size, Trends, and Forecast

According to the new market research report " Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021 ", published by MarketsandMarkets™, The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

Don’t miss out on business opportunities in Vaccine Adjuvants Market

Browse and in-depth TOC on "Vaccine Adjuvants Market"

90 - Tables
42 - Figures
156 - Pages

Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.
The major players in the vaccine adjuvants market are Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).

Read More Report @ https://www.marketsandmarkets.com/Market-Reports/vaccine-adjuvants-market-152603894.html

Value Addition for the Buyer:

This report aims to provide insights into the global vaccine adjuvants market. It provides valuable information on the product type, route of administration, disease type, applications, and application categories in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market.

To know about the assumptions considered for the study, download the pdf brochure

Drug Screening Market: Staregic Developments in Emerging Markets

The drug screening market is expected to reach USD 8.63 Billion by 2022 from USD 5.32 Billion in 2017, at a CAGR of 10.2%

Factors such as growing drug & alcohol consumption, enforcement of stringent laws mandating drug and alcohol testing, and the availability of government funding in major markets are driving the growth of this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773

Drug screening market segmentation:

•             based on products

•             based on diseases

•             based on techniques,

•             based on end users

•             based on regions.

The Major Players Opearting in the Drug screening Market:

Most key players adopted product launches as the primary growth strategy between 2014 and 2017. Some of the companies that adopted this strategy include Alfa Scientific Designs, Thermo Fisher, and Premier Biotech.

Geographical Detailed Analysis for Drug screening Market:

North America is expected to dominate the market followed by Europe. The large share of this geographical segment is attributed to factors such as growing consumption of illicit drugs, the availability of government funding to curb drug addiction, presence of laws supporting drug screening, and growing burden of road accidents due to alcohol consumption in the region.

The drug screening market is highly competitive with the presence of several small and big players. Some of the players offering products for drug screening market include Alere (US), Thermo Fisher (US), Siemens Healthineers (Germany), Alfa Scientific Designs (US), Roche (Switzerland), MPD, Inc. (US), Shimadzu (Japan), OraSure (US), Lifeloc (US), and Drägerwerk (Germany). On the other hand, LabCorp (US), Quest Diagnostics (US), Psychemedics (US), Omega Laboratories (US), CRL (US), SureHire (Canada), and CannAmm (Canada).

Read More in Detailed (Drug screening Market ): 

https://www.marketsandmarkets.com/PressReleases/drug-alcohol-screening.asp

Global Genotyping Assay Market Trends, Report, Size, Share, Analysis and Forecast

The Genotyping Assay Market is projected to reach USD 31.9 billion by 2023 from USD 11.8 billion in 2018, at a CAGR of 22.0%. This study involved the extensive use of both primary and secondary sources.

The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Genotyping Assay Market segmentation:

·         Based on product

·         Based on technology

·         Based on Application

·         Based on End User

·         Based on Region

To know about the assumptions considered for the study download the pdf brochure, Here: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595

The Major Players Operating in the Genotyping Assay Market:

The prominent players in the genotyping assay market are Thermo Fisher Scientific (US), Illumina (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US) are some key players in this market. These companies are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies such as product launches, approvals & enhancements; expansion; agreements, collaboration & partnerships; and acquisition.

Geographical Detailed Analysis for Genotyping Assay Market:

North America is expected to account for the largest share of the genotyping assay market in 2018, followed by Europe and the Asia Pacific. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region, along with an increasing demand from pharmaceutical companies for genotyping products and rising investments by government bodies, are responsible for the large share of the North American genotyping market.

Read More in Detailed (Genotyping Assay Market):  https://t.ly/O6wJ

Radiotherapy Market | Emerging Trends and Global Industry Dynamics

Growth in the market is mainly driven by the increasing use of medical imaging modalities due to the rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in the installed base of radiology equipment, and growing awareness on radiation dose management.

The radiation dose management market is projected to reach USD 447 million by 2024 from USD 206 million in 2019, at a CAGR of 16.7% during the forecast period.

The rising focus on interventional radiology and nuclear medicine is expected to provide growth opportunities for players in the radiation dose management market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82326344

Radiation dose management market segmentation:

·         based on product & service

·         based on modality

·         based on end users

The Major Players Opearting in the Radiation dose management market:

Key players in the global radiation dose management industry are Bayer AG (Germany), GE Healthcare (US), PACSHealth, LLC (US), and Sectra Medical Systems (Sweden). Other prominent players in this market include Philips Healthcare (Netherlands), Fujifilm Holdings Corporation (Japan), Novarad Corporation (US), Siemens Healthineers (Germany), Agfa HealthCare (Belgium), Canon (Japan), and Qaelum N.V. (Belgium).

In 2018, Bayer AG held the leading position in the market. The company has a wide geographical presence spanning North America, Europe, Asia Pacific, and Latin America. The company’s strong brand recognition and extensive product portfolio in the radiation dose management market is its key strength. GE Healthcare held the second position in the radiation dose management market in 2018.

Geographical Detailed Analysis for Radiation dose management market:

The radiation dose management market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of the radiation dose management market. The large share of North America can be attributed to factors such as the stringent legislative and accreditation requirements regarding the reporting and optimization of radiation doses, high adoption of HCIT technologies, and the presence of stringent regulatory requirements regarding patient safety.

Read More in Detailed (Radiation dose management market):

https://www.marketsandmarkets.com/PressReleases/radiation-dose-management.asp